Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 100

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 100
---
          |  36,803,942 |   |     |                |  39,464,764 |   |
| Accumulated other comprehensive income                                                                                             |     |        |     135,471 |   |     |          |     135,471 |   |     |                |     135,471 |   |
| Accumulated deficit                                                                                                                |     |        | (40,527,957 | ) |     |          | (40,527,957 | ) |     |                | (40,527,957 | ) |
| Total stockholders’ equity                                                                                                         |     | $      |   3,955,006 |   |     | $        |   5,898,448 |   |     | $              |   8,559,345 |   |
| Total capitalization                                                                                                               |     | $      |   4,102,125 |   |     | $        |   6,045,567 |   |     | $              |   8,706,464 |   |

| (1) | Does                       
 not include the following: |

| ● | 57,068 shares of common stock reserved for future issuance under the 2022 Plan; |

| ● | 1,379,870                                                                                   
 shares of common stock issuable upon exercise of outstanding warrants at a weighted average 
 exercise price of $22.50 per share;                                                         |

| ● | 137,637 shares of common stock issuable upon exercise of outstanding options at a weighted average 
 exercise price of $13.92 per share;                                                                |

| ● | shares                                                                                     
 of common stock issuable upon the conversion of 76,480 shares of Series A Preferred Stock. |

58 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Prospective investors should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this annual report. Some of the information contained in this discussion and analysis or set forth elsewhere in this annual report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements. ” This discussion should be read in conjunction with our audited consolidated financial statements and the notes thereto included elsewhere in this report. In this discussion, we may use certain non-generally accepted accounting